Key facts
- Biobot Analytics’s last known valuation is $126.8M (Oct 2021).
- It has raised $41.2M across 3 recorded rounds; the latest was Early Stage VC ($13.5M) in May 2025.
- Notable investors include Y Combinator, Pioneer Fund, Soma Capital, Liquid 2 Ventures, Dorm Room Fund — 38 tracked in total.
- Biobot Analytics has filed 4 Form Ds with the SEC since 2020, most recently Jun 2025 ($13.5M sold to 46 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 38 names
- ·Watchlist + deal alerts for Biobot Analytics
Funding rounds
3 roundsAbout Biobot Analytics
Developer of a wastewater analysis tool designed to deliver untapped insights into human health and behavior. The company's tool generates public health data that is naturally anonymized to yield insight into the health communities and sells data as a service, building and monetizing proprietary datasets and providing analytics via the dashboard for viruses (influenza, RSV, norovirus, Hep C) and chemical metabolites, enabling government officials to get access to actionable insights to prioritize interventions and tackle public health proactively.
- Sector
- Information Technology
- HQ
- Cambridge, MA, United States
- Founded
- 2017
- Employees
- 28
- Website
- biobot.io/
- Ownership
- Privately Held (backing)
Biobot Analytics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biobot Analytics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biobot Analytics in its N-PORT filings yet. We sweep new filings monthly.